510: Creating New Compounds to Treat Central Nervous System Disorders - Dr. Al Robichaud

Dr. Al Robichaud is Chief Scientific Officer at Sage Therapeutics, a clinical-stage biopharmaceutical company committed to developing and commercializing novel medicines to treat life-altering central nervous system disorders. The team at Sage Therapeutics is focused on delivering new medicines for people with central nervous system disorders, such as depression. The compounds they have developed modulate the activity of receptors in the brain that respond to specific neurotransmitters. Outside of science, Al has been an avid scuba diver for most of his life. He particularly enjoys exploring the ocean in the Caribbean with his family. Al received his B.S. in chemistry from Rensselaer Polytechnic Institute. He worked as a staff chemist at FMC Corporation for about two years before returning to school to earn his PhD in Organic Chemistry from the University of California, Irvine. Al next conducted research as an American Cancer Society postdoctoral fellow in organic chemistry at Colorado State University. Before joining the team at Sage Therapeutics, Al held positions at Merck Pharma, DuPont Merck Pharma, DuPont Pharmaceuticals, Bristol-Myers Squibb, Wyeth Pharmaceuticals, and Lundbeck Research. In our interview, Al tells us more about his life and science.